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Abstract 
Purpose: To develop a simple, adequately sensitive, and practical liquid chromatographic-mass 
spectrometric method to simultaneously quantify three tyrosine kinase inhibitors, viz, tofacitinib (TOF), 
cabozantinib (CBZ) and afatinib (AFB) after their extraction from both human plasma and urine.  
Methods: Blood and urine samples were obtained from healthy volunteers who admitted to not being 
on any medications. The investigated analytes were chromatographically separated on a C18 column 
(Luna®-PFP 100Å column, 50 mm × 2.0 mm i.d., 3.0 µm) with the aid of a mobile phase containing A; 
acetonitrile (ACN) and B; 0.01 M ammonium formate buffer (pH 4.1) pumped at a rate of 0.3 mL.min-1 in 
the ratio A:B, 50:50 v/v. Analyte monitoring was achieved by tandem mass spectrometry interfaced with 
an electrospray ionization source with the aid of multiple reaction monitoring (MRM) mode for analytes 
quantification.  
Results: The proposed method permitted a specific and sensitive determination of the investigated 
TKIs in the linear range of 1.0 - 100 ng mL-1 with correlation coefficient (r2) of 0.9991, 0.9997, and 
0.9998 for TOF, CBZ and AFB, respectively. The method was validated with regard to its limits of 
quantification (ranging from 0.91 to 1.24 ng mL-1 for the 3 analytes), intra- and inter assay accuracy (in 
the range -1.85 to 1.22 %) and precision (0.71 - 5.12 %). The method was also validated in terms of 
recovery from both studied matrices, robustness and matrix effect.  
Conclusion: The results obtained reveal that the developed method is simple, specific and highly 
efficient for routine determination of the studied analytes in human plasma and urine. It can be reliably 
applied for high throughput analysis of clinical samples containing the investigated analytes. 
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Tyrosine kinases (TKs) are deemed potential 
targets for new drug development, especially for 
cancer and rheumatoid arthritis drugs. Over the 
last decade, several tyrosine kinase inhibitors 
(TKIs) have been developed and approved for 
the treatment of various types of cancer, with 
each of them targeting specific signaling 
pathways [1,2]. Furthermore, more recent 
advances have also led to the discovery of the 
Janus kinases (JAKs) [3], which by their 
inhibition introduced new therapeutic approach 
for cancer and immunity disorders [4]. 
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In the current study a simple analytical procedure 
was designed to be able to simultaneously 
quantify various TKIs in human plasma, hence, 
three FDA approved medications were selected 
as representative examples of the TKIs acting on 
the different kinases. Firstly, afatinib (AFB; Fig 
1a), a selective TKI that blocks the signaling 
pathways from the receptor tyrosine kinases 
HER1 (EGFR/ErbB1), HER2 (ErbB2), and HER4 
(ErbB4) [5]. In 2013, the U.S. FDA approved the 
drug to be used with patients suffering of locally 
advanced or metastatic non-small cell lung 
cancer (NSCLC) with their tumors showing 
EGFR (epidermal growth factor receptor) 
mutations either as deletions of exon 19 or 
substitution of exon 21 [6].  
The second chosen TKI representative is 
cabozantinib (CBZ; Fig. 1b)), which is also an 
orally active agent that blocks the activity of 
different tyrosine kinases including 
mesenchymal–epithelial transition factor (MET) 
and vascular endothelial growth factor receptor 
types 1 (VEGFR-1), 2 (VEGFR-2), and 3 
(VEGFR-3) [7]. In 2011, the U.S. FDA approved 
CBZ for the management of patients with 
progressive, metastatic medullary thyroid cancer; 
in 2015 it was also approved by the European 
Medicines Agency (EMA) for the same use. The 
last chosen kinase inhibitor is tofacitinib (TOF; 
Figure 1c), which is a representative of the Janus 
kinase inhibitors (JAKIs). TOF is reported to 
selectively block the signaling pathway involving 
the kinases JAK 1 and 3 [8]. TOF was approved 
by the U.S. FDA in 2012 for the management of 
patients with moderate to severe rheumatoid 
arthritis (RA) either alone or to be taken with 
methotrexate in more sever un-responsive cases 
[9]. 
 
Screening of the literature disclosed few 
published reports for the quantification of AFB, 
CBZ, and TOF either alone or in combination 
with other medications. Determination of AFB 
alone was reported in two recent studies in 
human plasma using UPLC-DAD [10], LC-MS 
[11], with two other liquid chromatographic 
procedures published for its quantitation in 
tablets [12,13]. Moreover, one recent study 
reported AFB simultaneous determination with 
other TKIs namely, vandetanib, pazopanib, and 
dasatinib in human plasma using HPLC-DAD 
[14] with the AFB linearity range 0.7 - 7.0 µgmL-1, 
which is higher than its reported Cmax (maximum 
plasma concentration) value of 6.19 - 7.58 ngmL-
1 [11] and 11.6 - 40.8 ngmL-1 after administration 
of single and multiple doses of different AFB 
concentrations [15]. On the other hand, individual 
CBZ quantification was reported using HPLC-UV 
[16], LC-MS/MS [17,18] in rat plasma with one 
study using micellar enhanced spectrofluorimetry 
in human plamsa [19]. 
 
The reported Cmax of CBZ-depends mostly on its 
dose, which was in the range of 34.2-603 ngmL-1 
after oral administration of 0.08 mgkg-1 to 1.28 
mgkg-1. Ultimately, with its lowest reported 
observed plasma concentration ~ 81 ngmL-1 [20], 
quantitative determination of TOF alone was 
reported using HPLC-UV in rat plasma [21], for 
its enantiomers separation [22], using LC-MS 
alone [23], and in combination with methotrexate 
in rat plasma [24]. 
 
 
Figure 1: Chemical structures of the studied TKIs and IS. (Major errors in the structures of afatinib and tofacitinib; 
indicate “glibenclamide” as “glibenclamide (IS)”) 
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Hence, to date no study has been published for 
the determination of AFB, CBZ, and TOF 
although, as per clinical decisions, TOF as an 
anti-rheumatoid arthritis therapy may be 
administered with AFB or CBZ or any other TKI 
in patients suffering both diseases. This study is 
therefore conducted to establish and 
comprehensively validate a new LC-MS/MS 
method to simultaneously quantify AFB, CBZ, 





Chemicals and reagents 
 
Reference standards of AFB, CBZ, and TOF of > 
99 % purity were acquired from Weihua Pharma 
Co. Ltd (Zhejiang, China). Ultrapure solvents and 
reagents of HPLC-grade were obtained from 
Merck BDH Ltd. (Poole, U.K). Blood samples 
were obtained from King Khaled University 
Hospital (King Saud University, Riyadh, KSA), 
following informed consent was acquired, fasting 
blood specimen were collected, plasma was then 
separated and stored frozen at -70 °C. Human 
urine was obtained from healthy male volunteers 
who admitted to not being on any medications. 
The ethics review committee of the College of 
Pharmacy, King Saud University, Riyadh, Saudi 
Arabia approved the study protocol (approval no. 
14370511), which followed the international 
ethical guidelines for biomedical research 
involving human subjects [25]. A Milli-Q plus 
water purification system (Merck Millipore, MA, 
USA) was used to produce ultra-pure water ≥ 
18.2 MΩ that was used throughout the study. 
 
Instrumentation and conditions 
 
Chromatographic resolution of the analytes was 
executed through an Agilent 1200 HPLC system 
with their quantitative determination carried out 
using an Agilent 6410 triple quadrupole (Agilent 
Technologies, CA, USA). Analytes 
chromatographic elution was accomplished 
utilizing a mobile phase containing solvents A; 
Acetonitrile (ACN) and B; 0.01 M ammonium 
formate buffer (pH~4.1) pumped binarily at 0.3 
mLmin-1 in the ratio A:B, 50:50 v/v. A C18 
column (Luna®-PFP 100Å column) (50 mm × 2.0 
mm i.d., 3.0 µm) (Phenomenex Inc., CA, USA) 
was used for the analytes separation at ambient 
temperature. Following their elution, analytes 
were sprayed into the mass spectrometer using 
an ESI (electrospray ionization) interface running 
in the positive ionization mode with the ESI 
temperature set to 350 oC. Low and high purity 
nitrogen gas were used as desolvation gas 
flowing at 12 Lmin-1 and neubilizer gas with a 
pressure of 55 psi, respectively. Capillary voltage 
was set to 4 kV and a Dwell time of 200 ms was 
maintained, for all ions. All separation and 
detection parameters were adjusted to augment 
the chromatographic resolution and mass 
spectrometric response. The optimized MS 
parameters for individual parent and daughter 
ions are listed in Table 1. A MassHunter software 
(Agilent Technologies, CA, USA) was used 
throughout the study to control the LC-MS 
system and to acquire the data. 
 
Preparation of standard solutions  
 
AFB, CBZ, TOF, and IS Standard solutions of 
200 µg mL-1 were freshly prepared in methanol 
at room temperature. Further dilutions were 
carried out using methanol to achieve 10 µg mL-
1 working solutions. Further dilutions of each 
analyte were attained in mobile phase to prepare 
calibration and quality control (QC) samples. 
 
Calibration curves samples for plasma and 
urine 
 
Calibration curves were constructed in both 
spiked drug-free human plasma and urine with 
AFB, CBZ, and TOF concentrations in the 
concentration range 1.0 - 100 ng mL-1. Aliquots 
of 100 µL of AFB, CBZ, and TOF were spiked 
into 1 mL of human plasma/urine and appropriate 
volumes were then mixed with 350 µL of 0.1 M 
glycine buffer (pH ~9.0). 
 
 
Table 1: MS optimized parameters of the investigated analytes 
 








Time segment for 
MRM scan (min) 
TOF 313.2 165.0 135 20 0.0-1.3 
313.2 148.9 135 20 0.0-1.3 
AFB 486.1 371.0 140 30 1.3-2.0 
486.1 305.0 145 34 1.3-2.0 
IS 494.0 369.0 135 15 2.0-2.8 
494.0 168.9 135 15 2.0-2.8 
CBZ 502.2 391.1 135 32 2.8-4.0 
502.2 323.1 135 34 2.8-4.0 
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A volume of 50 μL of IS (200 ng mL-1) was added 
and subsequent liquid-liquid extraction was 
performed to those samples via the addition of 
diethyl ether (4 mL) succeeded by separation 
and evaporation of the organic phase under a 
gentle stream of nitrogen. Residues were 
reconstituted in mobile phase and filtered 
through a 0.45 μm Millex filter (Millipore, MA, 
USA). Additionally, three quality control samples 
of 7.0, 50, and 80 ng mL-1 and three solutions for 
incurred sample reanalysis (ISR) with 
concentrations of 10, 50, and 100 ng mL-1 were 
prepared in human plasma only. Blank 
plasma/urine samples were similarly treated with 
ultrapure water replacing the analytes solutions. 
 
Calibration curve construction 
 
Three calibration graphs of each analyte in both 
plasma and urine, were executed by plotting 
peak area ratio of each analyte to IS against the 
corresponding analyte concentrations using 1/X2 
as a weighing factor. Calibrator response 
functions and choice of regression analysis were 
chosen by evaluating the percentage relative 
error (% RE) for all calibrators as described by 






The method specificity was investigated via the 
analysis of 6 blank plasma/urine samples 
processed according the proposed procedure. 
The injected samples were subsequently 
examined for any elution interference compared 
to the analytes samples either in plasma or urine.  
 
Linearity and sensitivity 
 
Three different calibration graphs were plotted for 
plasma and urine samples, and were used to 
determine the method‘s linearity and sensitivity. 
Limit of detection (LOD) and lower limit of 
quantification (LLOQ) were estimated via 
equation 1, using the calibration curve slope (b) 
and standard deviation of the intercept (SD0). 
 
LLOQ or LOD = kSD0/b ………………….. (1) 
 
where k is 10 for LLOQ and 3.3 for LOD 
 
Precision and accuracy 
 
Intra- and inter-day assessments of both 
accuracy and precision were performed through 
the analysis of the QC samples 3 times in a 
single day and over 3 consecutive days, 
respectively. The coefficient of variation percent 
(%CV) was used as an indication of precision 
and was calculated as per equation 2 using the 
calculated mean and standard deviation values 
of each sample determination. 
 
(%CV) = [SD/M] x 100 .................………….  (2) 
 
where M is the mean measured concentration. 
Percent error (% error) was used to refer to the 
accuracy of those samples determinations and 
computed following equation 3. 
 
% Error = [(M-N)/N] x 100 ............................ (3) 
 
where N is the nominal concentration. 
 
Furthermore, the 3 ISR samples were assessed 
and their mean concentrations were calculated 
and set as initial values (I), a week later those 
samples were reanalyze yielding their “repeat 
values”. The difference (% D) in ISR samples 
was then computed as in equation 4. 
 
% D = [(I-R)/V] x 100 .................................. (4) 
 
where V is the mean of initial and repeat values 
of each sample. 
 
Recovery and matrix effect 
 
Analytes recovery was determined in both 
matrices to infer the extraction efficiency of the 
current procedure. Recoveries were evaluated by 
comparing the mean peak area ratio of each 
analyte to IS in the extracted QC samples to 
those extracted from blank plasma and urine, 
which were exposed to post-spiking with the 
respective reference solutions.  
 
For calculation of absence of matrix effect (% A) 
for both matrices, Eq 3 was used.  
 
%A = (B/C) x 100 ............................ (5) 
 
where B and C are the mean peak area ratio of 





Robustness of the proposed analytical procedure 
was investigated by examining the influence of 
individual modifications/changes within the 
analytical settings around the proposed optimum 
value in the current procedure. Those inter-
varied parameters reflect probable alterations 
occurring in diverse test environments. The 
modified mobile phase parameters were the 
composition ratio of A and B, flow rate, and pH of 
solvent B. 
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MRM chromatograms representing plasma 
samples of the analytes under the 
aforementioned chromatographic and mass 






Figure 3 demonstrates the MS spectra produced 
during the product ion (MS2) and MRM scans of 
the investigated TKIs. Hence, the current method 
was proved specific with the absence of 
interfering signals in blank plasma samples 
within the elution time period of the analytes. 
 
Linearity and sensitivity 
 
Calibration curves in both plasma and urine 
samples of the studied TKIs provided linear 
relationships with low standard deviations for all 
calibration. Table 2 summarizes the different 
analytical parameters including the LOD and 
LLOQ, which were computed to be below the 
reported Cmax values [15,20,27] of the studied 
TKIs. 
 
Precision and accuracy 
 
Accuracy and precision of the present method 
were evaluated on intra- and inter- day basis as 
previously described, the results listed in Table 3 
proved the method’s efficiency with the 
demonstrated low CV% and RE. In a similar vein, 
3 concentrations of 10, 50, and 100 ng mL-1 of 
the studied TKIs in spiked human plasma were 
assayed for incurred sample re-analysis and 
Table 4 clearly shows that their results confirmed 
the current method reproducibility. 
 
Effect of different matrices on analyte 
recovery 
 
Recovery data of the investigated TKIs were 
computed and are listed in Table 5. Moreover, 
and for further confirmation of the absence of any 
matrix effect, two groups of three samples of 
blank plasma and urine were extracted and then 
spiked with the lowest QC concentration of the  
 
Figure 2:  MRM chromatograms of a) double blank human plasma (without analytes and IS); b) blank human 
plasma with IS; c) Overlaid MRM chromatograms of TOF, AFB, IS, and CBZ in spiked human plasma samples 
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Figure 3: MS2 and MRM spectra of TOF, AFB, and CBZ. 
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analytes (i.e. 7.0 ng mL-1) and the IS. 
Concomitantly, another group with three samples 
of the same concentration and IS in aqueous 
solution (i.e. in mobile phase) was prepared. The 
different sample groups were analyzed and the 
absence of matrix effect percent was evaluated 
and listed in Table 5. 
 
Table 2: Analytical parameters of the current 
analytical procedure 
 
Parameter TOF CBZ AFB 
Retention 
time (min) 
0.835 3.231 1.507 
Linearity 
(ng mL-1) 
1.0-100 1.0-100 1.0-100 
Intercept 
±SD 
1.98±0.06 2.87±0.09 2.88±0.14 
Slope ±SD 0.49±0.01 1.08±0.02 1.33±0.01 
LOD (ng 
mL-1) 
0.41 0.29 0.34 
LLOQ (ng 
mL-1) 








Robustness was expressed by the relative 
standard deviation of the recovery results 
obtained from triplicate analysis of the studied 
TKIs in spiked human plasma with the inter-
varied analytical parameters. Table 6 
demonstrates the current method robustness 
showing the results acquired following the 
modification of the investigated parameters from 





Preliminary chromatographic and mass 
spectrometric optimizations were carried out in 
terms of mobile phase composition, flow rate, pH 
of the mobile phase, MRM transitions, etc. 
Subsequently, a mobile phase composed of ACN 
(A) and 0.01 M ammonium formate in water (pH 
~ 4.1) (B) (A:B, 50:50, v/v) was chosen for 
analytes separation and elution at a flow rate of 
0.3 mLmin-1. The use of MRM scanning protocol 
has enhanced the quantitative sensitivity of the 
method and eliminated any interference arising 
from the effects of the different matrices during 
the analytes elution. Following method 
development, the proposed method was 
validated according to the International 
Conference on Harmonisation (ICH) [56,57] and 
the U.S. Food and Drug Administration (FDA) 
guidance [58]. Validation was conducted with 
regard to specificity, linearity, sensitivity, intra- 
and inter-day accuracy and precision, 
robustness, and recovery from the both human 
plasma and urine. The recovery results clearly 
demonstrate the absence of endogenous matrix 
interference as the matrix effect is inferred if the 




A rapid, specific and sufficiently sensitive LC-
MS/MS method has been successfully developed 
and validated for the simultaneous quantification 
of the tyrosine kinase inhibitors TOF, CBZ, and 
AFB in human plasma and urine. The developed 
protocol allowed linear fitting of the analyte 
concentration with peak area ratio in the range of 
(1.0 - 100 ng mL-1) for all analytes. LLOQ values 
are 1.24, 0.91 and 1.05 ng mL-1 for TOF, CBZ, 
and AFB, respectively. The developed method is 
simple and efficient and can be used in 
pharmacokinetics studies as well as in the 







The authors would like to extend their sincere 
appreciation to Deanship of Scientific Research 
at King Saud University for funding Research 
Group no. RG-1435-025. 
 
Conflict of Interest 
 
No conflict of interest associated with this work. 
 
Contribution of Authors 
 
The authors declare that this work was done by 
the authors named in this article and all liabilities 
pertaining to claims relating to the content of this 
article will be borne by them. 
 
Open Access  
 
This is an Open Access article that uses a 
funding model which does not charge readers or 
their institutions for access and distributed under 
the terms of the Creative Commons Attribution 
License (http://creativecommons.org/licenses/by 
/4.0) and the Budapest Open Access Initiative 
(http://www.budapestopenaccessinitiative.org/rea
d), which permit unrestricted use, distribution, 
and reproduction in any medium, provided the 
original work is properly credited. 
Kadi et al 
Trop J Pharm Res, December 2016; 15(12): 2690  
 
 
Table 3:  Intra- and inter-day accuracy and precision values of the proposed analytical procedure 
 
Parameter Intra-day Inter-day 








6.95 49.85 80.01 6.98 49.98 79.95 6.97 50.14 80.98 6.92 49.08 78.89 6.92 49.17 78.78 6.90 48.85 78.95 
Accuracy 
(RE%) 
-0.71 -0.31 0.07 -0.27 -0.04 -0.06 -0.41 0.29 1.22 -1.20 -1.85 -1.38 -1.08 -1.66 -1.52 -1.41 -2.3 -1.32 
Precision 
(CV%) 
0.71 3.28 3.26 1.85 3.78 2.40 2.97 2.24 3.73 3.43 3.96 4.39 4.43 5.12 4.57 3.43 4.90 4.01 
 
Table 4: Results of the incurred sample reanalysis of the studied analytes in spiked human plasma (n=3) 
 
Parameter TOF CBZ AFB 
 Nominal conc. (ng mL-1) 10 50 100 10 50 100 10 50 100 
Mean initial measured 
concentration (ng mL–1) 
9.98 49.95 100.14 9.89 50.17 99.78 10.08 49.89 100.57 
Mean repeat measured 
concentration (ng mL–1) 
9.87 49.21 99.59 9.68 48.76 99.09 9.85 48.69 99.17 
Difference (%) 1.18 1.48 0.55 2.18 2.85 0.69 2.32 2.45 1.39 
 
Table 5: Recovery data for the studied analytes in human plasma and urine 
 
Parameter Human plasma Human urine 




7.0 50 80 7.0 50 80 7.0 50 80 7.0 50 80 7.0 50 80 7.0 50 80 
Recovery 
(%) 
98.44 97.92 98.74 98.87 99.78 99.83 98.14 99.56 98.89 99.81 100.03 99.80 100.21 100.25 98.69 99.39 98.38 99.73 
Precision 
(%RSD)  




98.46 - - 96.29 - - 97.79 - - 97.70 - - 96.85 - - 95.42 - - 
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Table 6: Recovery of the analyzed TKIs in spiked human plasma as an indication of the method’s robustness 
 
Parameter Recovery from spiked human plasma (± RSD%) 
 TOF CBZ AFB 
Optimum conditions* 98.37±2.82 99.49±3.59 98.86±2.83 
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